1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bioextrax AB

Bioextrax AB

2.19
SEK
+0.02
(+0.92%)
-0.42EPS
116.47MMarket Cap
Nov 20Next Earn
Bioextrax AB
STO:BIOEX
(Nasdaq Stockholm)

Recent

price

2.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
- -
- -
- -
- -
0.02
0.02
0.08
0.02
0.02
0.01
Revenue per Share
-0.01
- -
-0.06
-0.19
-0.42
-0.78
-1.09
-0.81
-0.52
-0.45
-0.43
Basic EPS, GAAP
-0.01
- -
0.03
-0.36
-0.33
-0.7
-1.03
-0.87
-0.57
-0.66
-0.36
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.02
0.03
0.12
0.13
0.45
1.23
0.69
0.66
0.53
0.25
Book Value per Share
- -
0.02
0.03
0.12
0.13
0.45
1.23
0.69
0.66
0.53
0.25
Tangible Book Value per Share
15
15
15
10
13
14
17
27
33
40
43
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
2
1
1
1
Sales/Revenue/Turnover
- -
670
- -
- -
-25,573.09
-3,814.86
-4,725.82
-1,050.54
-3,405.63
-2,356.54
-3,427.71
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Depreciation Expense
- -
- -
-1
-2
-6
-11
-19
-22
-17
-18
-19
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
580
- -
- -
-25,586.15
-3,815.94
-4,725.82
-1,046.06
-3,366.6
-2,338.84
-3,407.52
Profit Margin (%)
- -
- -
- -
1
1
6
24
13
16
2
6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
1
2
7
32
21
26
21
12
Total Equity
- -
41.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
43.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
43.12
-365.02
-260.52
-386.17
-230.14
-95.08
-82.24
-74.42
-74.9
-124.01
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
48
48
Market Capitalization
112
133
116

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6
13
9
Cash, Cash Equivalents & STI
4
12
7
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
2
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
130.01%
-18.59%
Free Cash Flow
- -
51.33%
37.94%
Net Income, GAAP
- -
32.84%
2.12%
Sales/Revenue/Turnover
- -
320.62%
46.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
-0.15
-0.11
-0.11
-0.52
2025
-0.1
-0.11
-0.11
-0.13
-0.45
2026
-0.09
-0.1
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Bioextrax AB (publ) is a Swedish biotechnology company focused on developing and commercializing advanced bio-based extraction solutions. The firm's proprietary platform technology facilitates the sustainable conversion of organic waste and raw materials into various eco-friendly products. Using a completely chemical-free and bio-based method, it recovers bioplastics (PHA) granules from diverse carbon sources, alongside producing organic hydrolyzed protein, keratin microfibres, bio-oils, and amino acids from materials such as poultry feathers. Established in 2014 and headquartered in Lund, Sweden, the company operates on a licensing model, providing its patented process technologies and expertise to material producers aiming for more cost-effective and environmentally sound manufacturing. Bioextrax continues to expand its collaborations, as evidenced by recent extended partnerships with chemical companies, underscoring its commitment to advancing green solutions and fostering a circular economy.